Skip to Main content Skip to Navigation
Journal articles

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Abstract : Introduction: Papillary renal cell carcinoma (PRCC) represents 10%e15% of renal carcinomas. No standard treatments exist for metastatic PRCC (mPRCC) patients. Axitinib is indicated as second-line treatment in metastatic clear cell renal carcinoma, and we aim to assess the efficacy of this vascular endothelial growth factor receptor inhibitor in front line for mPRCC. Methods: This French multicentre phase II study AXIPAP enrolled untreated mPRCC patients, with measurable disease, Eastern Cooperative Oncology Group performance status 1 and Vascular endothelial growth factor; VEGF inhibitor; Targeted therapy adequate organ functions. PRCC had to be confirmed by histology expert central review. Axi-tinib was administered orally 5 mg twice daily. Primary end-point was progression-free rate at 24 weeks (24w-PFR) by central review. Results: Fifty-six patients were screened, and 44 included (13 type 1, 30 type 2 and 1 non-specified). The median follow-up was 32.0 (13.1e39.9) months. The 24w-PFR was 45.2% (95% confidence interval [CI], 32.6% to þN), the objective response rate was 28.6% (95% CI, 15.7%e44.6%) (type 1: 7.7%; type 2: 35.7%). The overall median progression free survival was 6.6 months (95% CI, 5.5e9.2), 6.7 months (95% CI, 5.5e9.2) and 6.2 months (95% CI, 5.4 e9.2) for type 1 and 2, respectively. Median overall survival was 18.9 months (95% CI, 12.8enot reached). Adverse events were as expected; grade 3e4 treatment-related adverse events were rare except hypertension (27%). Conclusions: Axitinib demonstrated encouraging efficacy in mPRCC patients, especially in type 2 PRCC. Toxicity was manageable. Axitinib appears as an interesting option for first-line treatment and to be worth further investigation in combination with immunotherapy in these patients. Expert pathology review should be recommended in this setting. Clinical trial registration: ClinicalTrials.gov, NCT02489695.
Document type :
Journal articles
Complete list of metadatas

Cited literature [30 references]  Display  Hide  Download

https://hal-univ-lyon1.archives-ouvertes.fr/hal-02552562
Contributor : Sylvie Negrier <>
Submitted on : Thursday, July 23, 2020 - 4:47:35 PM
Last modification on : Friday, August 14, 2020 - 11:45:25 AM
Long-term archiving on: : Wednesday, September 23, 2020 - 8:12:40 PM

Files

AXIPAP VF EJC HAL UCBL.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Sylvie Négrier, Nathalie Rioux-Leclercq, Céline Ferlay, Marine Gross-Goupil, Gwénaelle Gravis, et al.. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer, Elsevier, 2020, 129, pp.107 - 116. ⟨10.1016/j.ejca.2020.02.001⟩. ⟨hal-02552562⟩

Share

Metrics

Record views

44

Files downloads

102